Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New mutations in leukemia: Researchers found mechanism that can help design future therapies

05.09.2011
Results will be published next Sunday in Nature Genetics

An international team of researchers has found a group of mutations involved in T-cell acute lymphoblastic leukemia (T-ALL), and showed that certain drugs, already in clinical use to treat other diseases, can eliminate the cells carrying these mutations.

Results* will be published next week in Nature Genetics and may promote the development of novel therapeutic approaches against leukemia.

The study was led by researcher João T. Barata at Instituto de Medicina Molecular in Lisbon, Portugal, jointly with J. Andres Yunes at Centro Infantil Boldrini in Campinas, São Paulo, Brazil, in collaboration with researchers from the National Cancer Institute in Frederick, Maryland, USA, the Erasmus Medical Center, Rotterdam, The Netherlands; and other laboratories in Europe and the US.

This is a basic research study with potential clinical impact, which was performed, in part, using samples from pediatric leukemia patients.

T-ALL affects mostly children. It is a blood cancer consisting in an uncontrolled growth in the number of T-lymphocytes (white blood cells from the immune system).

The onset of the disease can be triggered by different genetic mutations in genes involved in the proliferation and differentiation of T-cells.

The identification and study of mutations found in leukemia patients is particularly important to help develop more efficient and targeted therapies. Researchers now found a group of mutations that affect 9% of the patients with T-ALL and that may originate leukemia in these patients.

Most importantly, researchers demonstrated that a set of pharmaceutical drugs can eliminate the effect of these mutations, unraveling a potential therapeutic application for their discovery.

The current study shows that the mutations occur at the gene coding for a protein localized at the surface of T-cells, the interleukin-7 receptor (IL7R).

This protein contacts with both the exterior and the interior of the cells, acting as a bridge to transfer chemical information from the outside to the inside of cells. Information transfer occurs upon the binding of a bloodstream protein (interleukin-7) to the receptor, which triggers a cascade of cellular reactions that are essential for the correct development and proliferation of T-cells.

In the new study, researchers also found that the mutations promote non-stop, uncontrolled T-cell proliferation, independently of extracellular triggers. This capacity to induce cells to grow relentlessly is associated with the ability to originate tumors.

To help fighting the tumors that contain IL7R mutations, the team of researchers studied pharmaceutical drugs known to act in several steps of the referred cascade of cellular reactions and found that these drugs - which are already being tested against other diseases such as rheumatoid arthritis – can stop cell proliferation induced in mutated cells and promote the elimination of these cells.

Says João T. Barata: "We discovered that the interleukin-7 receptor, which is essential for proper T-cell development, may also have a "dark side", acting as a Mr. Hyde of sorts. In particular, we found that certain mutations in this gene are involved in pediatric T-cell acute lymphoblastic leukemia and characterized how they act. Our observations allowed us to identify potential therapeutic weapons against these tumors. Although pediatric acute lymphoblastic leukemia is among the success stories in cancer therapy, improvements are still needed. We hope our findings will help further increase the efficacy and selectivity of already existing treatments."

Says J. Andrés Yunes, from Centro Infantil Boldrini in Campinas, São Paulo, Brazil: "Most mutations found resulted in the insertion of a cystein aminoacid into the IL7R. It is this new cystein that perverts the normal functioning of the receptor by linking two mutant IL7R molecules through disulfide bonds. I'm eager to know what is the probability of having a cystein codon insertion, in this specific location of the gene, to address whether this is random or not."

Says Scott K. Durum, from the National Cancer Institute in Frederick, Maryland, USA: "On the one hand, the IL-7 receptor should have seemed a likely cause of cancer because it normally stimulates cells to grow, which is what cancer cells do. On the other hand this seemed unlikely because there are normally two chains involved in signaling. However these remarkable mutations in just one of the chains circumvent the need for the second chain. In addition to existing drugs that can target this pathway, we aim to develop new antibodies against IL-7 receptor to treat these patients. "

This research was funded by several funding agencies, in particular by the Portuguese Foundation for Science and Technology (FCT - Fundação Portuguesa para a Ciência e a Tecnologia), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), and the intramural program of the National Cancer Institute, NIH.

* Title: "Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia", authors: Priscila P. Zenatti, Daniel Ribeiro, Wenqing Li, Linda Zuurbier, Milene C. Silva, Maddalena Paganin, Julia Tritapoe, Julie A. Hixon, André B. Silveira, Bruno A. Cardoso, Leonor M. Sarmento, Nádia Correia, Maria L. Toribio, Jörg Kobarg, Martin Horstmann, Rob Pieters, Silvia R. Brandalise, Adolfo A. Ferrando, Jules P. Meijerink, Scott K. Durum, J. Andrés Yunes and João T. Barata

Marta Agostinho | EurekAlert!
Further information:
http://www.fm.ul.pt

More articles from Health and Medicine:

nachricht Why might reading make myopic?
18.07.2018 | Universitätsklinikum Tübingen

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Scientists uncover the role of a protein in production & survival of myelin-forming cells

19.07.2018 | Life Sciences

In the ocean's twilight zone, tiny organisms may have giant effect on Earth's carbon cycle

19.07.2018 | Earth Sciences

Lying in a foreign language is easier

19.07.2018 | Social Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>